HS-10370 + adebrelimab + pemetrexed + carboplatin

This combination is a multi-drug regimen likely investigated for treatment of advanced solid tumors, particularly non-small cell lung cancer (NSCLC) with KRAS G12C mutations. - **HS-10370** is an orally bioavailable, selective, covalent inhibitor of KRAS G12C, developed for advanced solid tumors with this mutation[1][4][7][10]. - **Adebrelimab** is a humanized monoclonal antibody against PD-L1, acting as an immune checkpoint inhibitor, which restores antitumor immune activity. - **Pemetrexed** is a multi-targeted antifolate chemotherapy agent inhibiting thymidylate synthase and other folate-dependent enzymes, primarily used in non-squamous NSCLC and mesothelioma[2][3][6][8]. - **Carboplatin** is a platinum-based DNA crosslinking agent that is also standard for NSCLC and other cancers[2][3][6][8]. The regimen combines molecular-targeted therapy, immunotherapy, and cytotoxic chemotherapy to attack tumor pathways and harness immune response.

Other names

adebrelimabpemetrexedcarboplatin